Distribution of the Most Common Genetic Variants Associated with a Variable Drug Response in the Population of the Republic of Macedonia

1. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011; 63(2): 437-459.10.1124/pr.110.00353321436344Search in Google Scholar

2. Foster MW, Sharp RR. Race, ethnicity, and genomics: Social classifications as proxies of biological heterogeneity. Genome Res. 2002; 12(6): 844-850.10.1101/gr.9920212045138Search in Google Scholar

3. Stranger BE, Stahl EA, Raj T. Progress and promise of genome-wide association studies for human complex trait genetics. Genetics. 2011; 187(2): 367-383.10.1534/genetics.110.120907303048321115973Search in Google Scholar

4. Li J, Zhang L, Zhou H, Stoneking M, Tang K. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum Mol Genet. 2011; 20(3): 528-540.10.1093/hmg/ddq49821081654Search in Google Scholar

5. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scale. Pharmacogenet Genomics. 2009; 19(2): 170-179.10.1097/FPC.0b013e32831ebb3019151603Search in Google Scholar

6. Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, et al. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 2010; 20(8): 1020-1036.10.1101/gr.103341.109290956720538623Search in Google Scholar

7. McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012; 8(3): 371-382.10.1517/17425255.2012.65762622288606Search in Google Scholar

8. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects. Pharmacogenomics J. 2013; 13(1): 1-11.10.1038/tpj.2012.4523089672Search in Google Scholar

9. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009; 41(2): 89-295.10.1080/0360253090284348319514967Search in Google Scholar

10. Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, et al. The AmpliChip CYP450 test: Cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009; 9(1): 34-41.10.1038/tpj.2008.718591960Search in Google Scholar

11. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007; 17(2): 93-101.10.1097/01.fpc.0000239974.69464.f217301689Search in Google Scholar

12. Kalow W. Pharmacogenetics: A historical perspective. In: McLeod HL, DeVane CL, Haga SB, Johnson JA, Knoel DL, Kolesar JM, et al., Eds. Pharmacogenomics: Application to Patient Care, 2nd ed. Lenexa, KS: American College of Clinical Pharmacy. 2009: 22-31.Search in Google Scholar

13. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002; 48(10): 1668-1671.10.1093/clinchem/48.10.1668Search in Google Scholar

14. Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther. 1999; 66(2): 185-192.10.1053/cp.1999.v66.10007200110460072Search in Google Scholar

15. Buzková H, Pechandová K, Slanar O, Perlik F. Frequency of single nucleotide polymorphisms of CYP-2D6 in the Czech population. Cell Biochem Funct. 2008; 26(1): 76-81.10.1002/cbf.140217311358Search in Google Scholar

16. Qumsieh RY, Ali BR, Abdulrazzaq YM, Osman O, Akawi NA, Bastaki SM. Identification of new alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in Emiratis. PLoS One. 2011; 6(12): e28943. doi: 10.1371/journal.pone.0028943.10.1371/journal.pone.0028943324523522216145Search in Google Scholar

17. Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res. 2004; 50(2): 195-200.10.1016/j.phrs.2004.01.00415177309Search in Google Scholar

18. Bozina N, Granić P, Lalić Z, Tramisak I, Lovrić M, Stavljenić-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J. 2003; 44(4): 425-428.Search in Google Scholar

19. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007; 21(4): 419-426.10.1111/j.1472-8206.2007.00510.x17635181Search in Google Scholar

20. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of Pglycoprotein in a Russian population. Eur J Clin Pharmacol. 2003; 59(4): 303-312.10.1007/s00228-003-0606-212879168Search in Google Scholar

21. Yamada H, Dahl ML, Lannfelt L, Viitanen M, Winblad B, Sjoqvist F. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol. 1998; 54(6): 479-481.10.1007/s0022800504979776439Search in Google Scholar

22. Falzoi M, Pira L, Lazzari P, Pani L. Analysis of CYP2D6 allele frequencies and identification of novel SNPs and sequence variations in Sardinians. ISRN Genet. 2013; 2013. Article ID 204560; http://dx.doi.org/10.5402/ 2013/204560.10.5402/2013/204560Search in Google Scholar

23. Jakovski K, Kapedanovska Nestorovska A, Labacevski N, Dimovski AJ. Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population of R. Macedonia. Pharmazie. 2013; 68(11): 893-898.Search in Google Scholar

24. Kapedanovska Nestorovska A, Cvetkovska Dimitrovska A, Suturkova Lj. Genetic profile of CYP2C19 polymorphisms in population from Republic of Macedonia. Macedonian Pharmaceutic Bull. 2011; 57(Suppl): 346-348.Search in Google Scholar

25. Jakovski K, Kapedanovska Netorovska A, Labacevski N, Dimovski AJ. Frequency of most common CYP3A5 polymorphisms in the healthy population of the Republic of Macedonia. Macedonian Pharmaceutic Bull. 2012; 58(1-2): 25-31.10.33320/maced.pharm.bull.2012.58.003Search in Google Scholar

26. Hildebrandt MA, Carrington DP, Thomae BA, Eckloff BW, Schaid DJ, Yee VC, et al. Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogenomics J. 2007; 7(2): 133-143.10.1038/sj.tpj.650040416801938Search in Google Scholar

27. Horsfall LJ, Zeitlyn D, Tarekegn A, Bekele E, Thomas MG, Bradman N, et al. Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann Hum Genet. 2011; 75(2): 236-246.10.1111/j.1469-1809.2010.00638.x21309756Search in Google Scholar

28. Polimanti R, Carboni C, Baesso I, Piacentini S, Iorio A, De Stefano GF, et al. Genetic variability of glutathione S-transferase enzymes in human populations: Functional inter-ethnic differences in detoxification systems. Gene. 2013; 512(1): 102-107.10.1016/j.gene.2012.09.11323043933Search in Google Scholar

29. Sterjev Z, Josifovski T, Panovski M, Sututkova L, Dimovski AJ. The SULT1A1 allele with low potential for estrogen inactivation is associated with reduced colorectal cancer risk in postmenopausal women. Balkan J Med Genet. 2005; 8(3-4): 43-48.Search in Google Scholar

30. Bajro MH, Josifovski T, Panovski M, Jankulovski N, Nestorovska AK, Matevska N, et al. Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer. Cancer Genet. 2012; 205(4): 163-167.10.1016/j.cancergen.2012.01.01522559977Search in Google Scholar

31. Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res. 2008; 14(3): 817-825.10.1158/1078-0432.CCR-07-042518245544Search in Google Scholar

32. Wang H, Wang J, Zhao L, Liu X, Mi W. Methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia-evidence from an updated meta-analysis including 35 studies. BMC Med Genet. 2012; 4: 13-77.10.1186/1471-2350-13-77345978822943282Search in Google Scholar

33. Acuña M, Eaton L, Cifuentes L, Massardo D. Genetic variants in the enhancer region of the thymidylate synthase gene in the Chilean population. Br J Clin Pharmacol. 2006; 61(6): 778-782.10.1111/j.1365-2125.2006.02595.x188512116722845Search in Google Scholar

34. Alzahrani AM, Ragia G, Hanieh H, Manolopoulos VG. Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia. Biomed Res Int. 2013; 2013: 315980. doi: 10.1155/2013/3159980. Search in Google Scholar

35. Matevska N, Josifovski T, Kapedanovska A, Sterjev Z, Serafimoska Z, Panovski M, et al. Methylenetetrahydrofolate reductase C677T polymorphism and risk of colorectal cancer in the Macedonian population. Balkan J Med Genet. 2008; 11(2):17-24.10.2478/v10034-008-0028-7Search in Google Scholar

36. Kapedanovska Nestorovska A, Sterjev Z, Serafimoska Z, Josifovski T, Petrusevska N, Suturkova L, et al. Thymidylate synthase enhancer region (TSER) 2R/3R polymorphisms as an independent risk factor for colorectal cancer in Macedonian population. Macedonian Pharmaceutic Bull. 2011; 57(Suppl): 348-349. Search in Google Scholar